Selected research
Industry Research
Ketorolac Tromethamine Industry Research Report 2026
Market perspective
The global Ketorolac Tromethamine market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Ketorolac Tromethamine is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Ketorolac Tromethamine is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Ketorolac Tromethamine is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Ketorolac Tromethamine include Teva, Sun Pharmaceutical, Sandoz, Mylan, Pfizer, Sagent Pharmaceuticals, Omeros Corporation, Gland Pharma Limited and Egalet US Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Ketorolac Tromethamine market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Ketorolac Tromethamine Market by Company
Teva
Sun Pharmaceutical
Sandoz
Mylan
Pfizer
Sagent Pharmaceuticals
Omeros Corporation
Gland Pharma Limited
Egalet US Inc.
Dr. Reddy’s Laboratories
Aurobindo Pharma
Apotex
Amphastar Pharmaceuticals
Allergan
Akorn
Ketorolac Tromethamine Segment by Type
Nasal
Oral tablet
Ophthalmic
Injection
Ketorolac Tromethamine Segment by Application
Hospital
Clinic
Others
Ketorolac Tromethamine Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Ketorolac Tromethamine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Ketorolac Tromethamine and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Ketorolac Tromethamine.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Ketorolac Tromethamine manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Ketorolac Tromethamine by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Ketorolac Tromethamine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Nasal
- Oral tablet
- Ophthalmic
- Injection
Applications
- Hospital
- Clinic
- Others
Companies covered
- Teva
- Sun Pharmaceutical
- Sandoz
- Mylan
- Pfizer
- Sagent Pharmaceuticals
- Omeros Corporation
- Gland Pharma Limited
- Egalet US Inc.
- Dr. Reddy’s Laboratories
- Aurobindo Pharma
- Apotex
- Amphastar Pharmaceuticals
- Allergan
- Akorn
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Ketorolac Tromethamine Market Size (2021-2032)
- 2.2.2 Global Ketorolac Tromethamine Sales (2021-2032)
- 2.2.3 Global Ketorolac Tromethamine Market Average Price (2021-2032)
- 2.3 Ketorolac Tromethamine by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Nasal
- 2.3.3 Oral tablet
- 2.3.4 Ophthalmic
- 2.3.5 Injection
- 2.4 Ketorolac Tromethamine by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Ketorolac Tromethamine Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Ketorolac Tromethamine Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Ketorolac Tromethamine Revenue of Manufacturers (2021-2026)
- 3.4 Global Ketorolac Tromethamine Average Price by Manufacturers (2021-2026)
- 3.5 Global Ketorolac Tromethamine Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Ketorolac Tromethamine, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Ketorolac Tromethamine, Product Type & Application
- 3.8 Global Manufacturers of Ketorolac Tromethamine, Established Date
- 3.9 Global Ketorolac Tromethamine Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Teva
- 4.1.1 Teva Company Information
- 4.1.2 Teva Business Overview
- 4.1.3 Teva Ketorolac Tromethamine Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Teva Ketorolac Tromethamine Product Portfolio
- 4.1.5 Teva Recent Developments
- 4.2 Sun Pharmaceutical
- 4.2.1 Sun Pharmaceutical Company Information
- 4.2.2 Sun Pharmaceutical Business Overview
- 4.2.3 Sun Pharmaceutical Ketorolac Tromethamine Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Sun Pharmaceutical Ketorolac Tromethamine Product Portfolio
- 4.2.5 Sun Pharmaceutical Recent Developments
- 4.3 Sandoz
- 4.3.1 Sandoz Company Information
- 4.3.2 Sandoz Business Overview
- 4.3.3 Sandoz Ketorolac Tromethamine Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Sandoz Ketorolac Tromethamine Product Portfolio
- 4.3.5 Sandoz Recent Developments
- 4.4 Mylan
- 4.4.1 Mylan Company Information
- 4.4.2 Mylan Business Overview
- 4.4.3 Mylan Ketorolac Tromethamine Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Mylan Ketorolac Tromethamine Product Portfolio
- 4.4.5 Mylan Recent Developments
- 4.5 Pfizer
- 4.5.1 Pfizer Company Information
- 4.5.2 Pfizer Business Overview
- 4.5.3 Pfizer Ketorolac Tromethamine Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Pfizer Ketorolac Tromethamine Product Portfolio
- 4.5.5 Pfizer Recent Developments
- 4.6 Sagent Pharmaceuticals
- 4.6.1 Sagent Pharmaceuticals Company Information
- 4.6.2 Sagent Pharmaceuticals Business Overview
- 4.6.3 Sagent Pharmaceuticals Ketorolac Tromethamine Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Sagent Pharmaceuticals Ketorolac Tromethamine Product Portfolio
- 4.6.5 Sagent Pharmaceuticals Recent Developments
- 4.7 Omeros Corporation
- 4.7.1 Omeros Corporation Company Information
- 4.7.2 Omeros Corporation Business Overview
- 4.7.3 Omeros Corporation Ketorolac Tromethamine Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Omeros Corporation Ketorolac Tromethamine Product Portfolio
- 4.7.5 Omeros Corporation Recent Developments
- 4.8 Gland Pharma Limited
- 4.8.1 Gland Pharma Limited Company Information
- 4.8.2 Gland Pharma Limited Business Overview
- 4.8.3 Gland Pharma Limited Ketorolac Tromethamine Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Gland Pharma Limited Ketorolac Tromethamine Product Portfolio
- 4.8.5 Gland Pharma Limited Recent Developments
- 4.9 Egalet US Inc.
- 4.9.1 Egalet US Inc. Company Information
- 4.9.2 Egalet US Inc. Business Overview
- 4.9.3 Egalet US Inc. Ketorolac Tromethamine Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Egalet US Inc. Ketorolac Tromethamine Product Portfolio
- 4.9.5 Egalet US Inc. Recent Developments
- 4.10 Dr. Reddy’s Laboratories
- 4.10.1 Dr. Reddy’s Laboratories Company Information
- 4.10.2 Dr. Reddy’s Laboratories Business Overview
- 4.10.3 Dr. Reddy’s Laboratories Ketorolac Tromethamine Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Dr. Reddy’s Laboratories Ketorolac Tromethamine Product Portfolio
- 4.10.5 Dr. Reddy’s Laboratories Recent Developments
- 4.11 Aurobindo Pharma
- 4.11.1 Aurobindo Pharma Company Information
- 4.11.2 Aurobindo Pharma Business Overview
- 4.11.3 Aurobindo Pharma Ketorolac Tromethamine Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Aurobindo Pharma Ketorolac Tromethamine Product Portfolio
- 4.11.5 Aurobindo Pharma Recent Developments
- 4.12 Apotex
- 4.12.1 Apotex Company Information
- 4.12.2 Apotex Business Overview
- 4.12.3 Apotex Ketorolac Tromethamine Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Apotex Ketorolac Tromethamine Product Portfolio
- 4.12.5 Apotex Recent Developments
- 4.13 Amphastar Pharmaceuticals
- 4.13.1 Amphastar Pharmaceuticals Company Information
- 4.13.2 Amphastar Pharmaceuticals Business Overview
- 4.13.3 Amphastar Pharmaceuticals Ketorolac Tromethamine Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Amphastar Pharmaceuticals Ketorolac Tromethamine Product Portfolio
- 4.13.5 Amphastar Pharmaceuticals Recent Developments
- 4.14 Allergan
- 4.14.1 Allergan Company Information
- 4.14.2 Allergan Business Overview
- 4.14.3 Allergan Ketorolac Tromethamine Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Allergan Ketorolac Tromethamine Product Portfolio
- 4.14.5 Allergan Recent Developments
- 4.15 Akorn
- 4.15.1 Akorn Company Information
- 4.15.2 Akorn Business Overview
- 4.15.3 Akorn Ketorolac Tromethamine Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Akorn Ketorolac Tromethamine Product Portfolio
- 4.15.5 Akorn Recent Developments
5 Global Ketorolac Tromethamine Market Scenario by Region
- 5.1 Global Ketorolac Tromethamine Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Ketorolac Tromethamine Sales by Region: 2021-2032
- 5.2.1 Global Ketorolac Tromethamine Sales by Region: 2021-2026
- 5.2.2 Global Ketorolac Tromethamine Sales by Region: 2027-2032
- 5.3 Global Ketorolac Tromethamine Revenue by Region: 2021-2032
- 5.3.1 Global Ketorolac Tromethamine Revenue by Region: 2021-2026
- 5.3.2 Global Ketorolac Tromethamine Revenue by Region: 2027-2032
- 5.4 North America Ketorolac Tromethamine Market Facts & Figures by Country
- 5.4.1 North America Ketorolac Tromethamine Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Ketorolac Tromethamine Sales by Country (2021-2032)
- 5.4.3 North America Ketorolac Tromethamine Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Ketorolac Tromethamine Market Facts & Figures by Country
- 5.5.1 Europe Ketorolac Tromethamine Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Ketorolac Tromethamine Sales by Country (2021-2032)
- 5.5.3 Europe Ketorolac Tromethamine Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Ketorolac Tromethamine Market Facts & Figures by Country
- 5.6.1 Asia Pacific Ketorolac Tromethamine Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Ketorolac Tromethamine Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Ketorolac Tromethamine Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Ketorolac Tromethamine Market Facts & Figures by Country
- 5.7.1 South America Ketorolac Tromethamine Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Ketorolac Tromethamine Sales by Country (2021-2032)
- 5.7.3 South America Ketorolac Tromethamine Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.8 Middle East and Africa Ketorolac Tromethamine Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Ketorolac Tromethamine Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Ketorolac Tromethamine Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Ketorolac Tromethamine Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Ketorolac Tromethamine Sales by Type (2021-2032)
- 6.1.1 Global Ketorolac Tromethamine Sales by Type (2021-2032) & (k units)
- 6.1.2 Global Ketorolac Tromethamine Sales Market Share by Type (2021-2032)
- 6.2 Global Ketorolac Tromethamine Revenue by Type (2021-2032)
- 6.2.1 Global Ketorolac Tromethamine Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Ketorolac Tromethamine Revenue Market Share by Type (2021-2032)
- 6.3 Global Ketorolac Tromethamine Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Ketorolac Tromethamine Sales by Application (2021-2032)
- 7.1.1 Global Ketorolac Tromethamine Sales by Application (2021-2032) & (k units)
- 7.1.2 Global Ketorolac Tromethamine Sales Market Share by Application (2021-2032)
- 7.2 Global Ketorolac Tromethamine Revenue by Application (2021-2032)
- 7.2.1 Global Ketorolac Tromethamine Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Ketorolac Tromethamine Revenue Market Share by Application (2021-2032)
- 7.3 Global Ketorolac Tromethamine Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Ketorolac Tromethamine Value Chain Analysis
- 8.1.1 Ketorolac Tromethamine Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Ketorolac Tromethamine Production Mode & Process
- 8.2 Ketorolac Tromethamine Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Ketorolac Tromethamine Distributors
- 8.2.3 Ketorolac Tromethamine Customers
9 Global Ketorolac Tromethamine Analyzing Market Dynamics
- 9.1 Ketorolac Tromethamine Industry Trends
- 9.2 Ketorolac Tromethamine Industry Drivers
- 9.3 Ketorolac Tromethamine Industry Opportunities and Challenges
- 9.4 Ketorolac Tromethamine Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst